OBI Portfolio Company Diamond Therapeutics Secures Multi-Million Dollar ARPA-H Funding for Generalized Anxiety Disorder Clinical Trial

May 11, 2026

Ontario Brain Institute (OBI) portfolio company Diamond Therapeutics has been awarded a multi-million dollar funding contract from the U.S. Advanced Research Projects Agency for Health (ARPA-H), marking a major milestone in the company's efforts to develop new treatments for generalized anxiety disorder (GAD).

The funding was awarded through ARPA-H's Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) initiative and will support a Phase 2 clinical trial of Diamond Therapeutics' GAD treatment. The trials will be led by Diamond Therapeutics USA in collaboration with Dr. Claudio Soares, Director of the Centre for Psychedelics Health and Research in Kingston, Canada, and Dr. Brian Pinkston and Cheryl Lowry of Florida-based Tactical Mind Solutions.

GAD affects millions of people worldwide, and existing treatment options leave many without adequate relief. Alongside advancing Diamond Therapeutics' clinical program, the trial will generate data to support ARPA-H's broader goal of validating the safety and effectiveness of rapid-acting therapies, including psilocybin.

Diamond Therapeutics is part of OBI's portfolio of neurotechnology and brain health companies working to translate research into real-world impact for patients across Ontario, Canada, and beyond.